チオリダジン
参考資料

1 2 3 4  “SHARED CARE PROTOCOL Thioridazine”. NHS Lothian Joint Formulary (March 2012). 18 May 2015時点のオリジナルよりアーカイブ。2021年11月26日閲覧。
↑  Shvartsburd, A; Sajadi, C; Morton, V; Mirabi, M; Gordon, J; Smith, RC (August 1984). “Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients”. Journal of Clinical Psychopharmacology 4 (4):  194–198. doi:10.1097/00004714-198408000-00004. PMID 6470190.
↑  “塩酸チオリダジン”. www.interq.or.jp. 2021年11月26日閲覧。
1 2  Purhonen, M; Koponen, H; Tiihonen, J; Tanskanen, A (November 2012). “Outcome of patients after market withdrawal of thioridazine: A retrospective analysis in a nationwide cohort”. Pharmacoepidemiology and Drug Safety 21 (11):  1227–1231. doi:10.1002/pds.3346. PMID 22941581.
↑  “WHO Pharmaceuticals Newsletter 2005, No. 04: REGULATORY MATTERS: Thioridazine - Sale discontinued in Canada”. Essential Medicines and Health Products Information Portal (World Health Organization) 4 (2):  p. 5. (2005年). http://apps.who.int/medicinedocs/en/d/Js8119e/1.12.html 28 October 2013閲覧。
↑  “Withdrawal of thioridazine”. Australian Prescriber 30 (3):  82. (June 2007). http://www.australianprescriber.com/magazine/30/3/article/891.pdf.
↑  Brunton, L. L.; Chabner, B.; Knollmann, B. C., eds (2011). Goodman & Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill. ISBN 978-0-07-162442-8
↑  Kirchner, V; Kelly, CA; Harvey, RJ (2001). “Thioridazine for dementia”. The Cochrane Database of Systematic Reviews (3):  CD000464. doi:10.1002/14651858.CD000464. PMC 7034526. PMID 11686961. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034526/.
↑  Declercq T (Mar 2013). “Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia”. Cochrane Database Syst Rev 3 (3):  CD007726. doi:10.1002/14651858.CD007726.pub2. hdl:1854/LU-3109108. PMID 23543555. https://espace.library.uq.edu.au/view/UQ:296637/UQ296637_OA.pdf.
1 2 3  “THIORIDAZINE HYDROCHLORIDE tablet, film coated [Mutual Pharmaceutical]”. DailyMed.   Mutual Pharmaceutical (September 2010). 28 October 2013閲覧。
↑  Fenton, M; Rathbone, J; Reilly, J; Sultana, A (July 2007). “Thioridazine for schizophrenia”. The Cochrane Database of Systematic Reviews (3):  CD001944. doi:10.1002/14651858.CD001944.pub2. PMC 6718212. PMID 17636691. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718212/.
↑  Keks, N.; McGrath, J.; Lambert, T.; Catts, S.; Vaddadi, K.; Burrows, G.; Varghese, F.; George, T. et al. (1994-11). “The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia” (英語). Acta Psychiatrica Scandinavica 90 (5):  358–365. doi:10.1111/j.1600-0447.1994.tb01607.x. ISSN 0001-690X. https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0447.1994.tb01607.x.
↑  “Martindale: The Complete Drug Reference”. Medicines Complete.   The Pharmaceutical Press (18 August 2010). 28 October 2013閲覧。
↑  “Selected adverse effects of antipsychotic medications for schizophrenia”. UpToDate.   Wolters Kluwer Health. 24 October 2013閲覧。
↑  Fornaro, P; Calabria, G; Corallo, G; Picotti, GB (July 2002). “Pathogenesis of degenerative retinopathies induced by thioridazine and other antipsychotics: a dopamine hypothesis”. Documenta Ophthalmologica 105 (1):  41–49. doi:10.1023/A:1015768114192. PMID 12152801.
↑  Scott, Alfred W. (1963-12-01). “Retinal Pigmentation in a Patient Receiving Thioridazine” (英語). Archives of Ophthalmology 70 (6):  775–778. doi:10.1001/archopht.1963.00960050777009. ISSN 0003-9950. PMID 14065014. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/627402.
↑  “Thioridazine”. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. (2012). https://www.ncbi.nlm.nih.gov/books/n/livertox/Thioridazine/
↑  PubChem Substance Summary: Mesoridazine National Center for Biotechnology Information.
↑  “Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin”. Clinical Pharmacology & Therapeutics 59 (3):  322–31. (Mar 1996). doi:10.1016/S0009-9236(96)80010-5. PMID 8653995.
↑  PubChem Substance Summary: Sulforidazine National Center for Biotechnology Information.
↑  Daniel WA, Syrek M, Ryłko Z, Kot M (2001). “Effects of phenothiazine neuroleptics on the rate of caffeine demethylation and hydroxylation in the rat liver”. Pol J Pharmacol 53 (6):  615–21. PMID 11985335. http://www.if-pan.krakow.pl/pjp/pdf/2001/6_615.pdf.
↑  “医薬品・医療用具等安全性情報１６２号”. www.mhlw.go.jp.   厚生労働省. 2021年11月26日閲覧。
↑  “DI月報  No. 220”.   山口大学. 2021年11月26日閲覧。
↑  “Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!”. Int. J. Antimicrob. Agents 35 (6):  524–6. (June 2010). doi:10.1016/j.ijantimicag.2009.12.019. PMID 20188526. https://hal.archives-ouvertes.fr/hal-00585817/file/PEER_stage2_10.1016%252Fj.ijantimicag.2009.12.019.pdf.
1 2  Amaral, L; Viveiros, M (May 2012). “Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections”. International Journal of Antimicrobial Agents 39 (5):  376–380. doi:10.1016/j.ijantimicag.2012.01.012. PMID 22445204.
↑  Thanacoody, HKR (November 2007). “Thioridazine: resurrection as an antimicrobial agent?”. British Journal of Clinical Pharmacology 64 (5):  566–574. doi:10.1111/j.1365-2125.2007.03021.x. PMC 2203271. PMID 17764469. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2203271/.
↑  Thorsing, M; Klitgaard, JK; Atilano, ML; Skov, MN; Kolmos, HJ; Filipe, SR; Kallipolitis, BH (May 2013). “Thioridazine Induces Major Changes in Global Gene Expression and Cell Wall Composition in Methicillin-Resistant Staphylococcus aureus USA300”. PLOS ONE 8 (5):  e64518. Bibcode: 2013PLoSO...864518T. doi:10.1371/journal.pone.0064518. PMC 3656896. PMID 23691239. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656896/.
↑  Deetz, Thomas R., et al. (2003). “Successful treatment of Balamuthia amoebic encephalitis: presentation of 2 cases”. Clinical infectious diseases 37 (10):  1304-1312. doi:10.1086/379020.